| cyclophosphamide |
180 |
| interstitial lung disease |
180, 239 |
| pirfenidone |
180 |
| connective tissue disease |
283 |
| hemoptysis |
283 |
| pediatrics |
283 |
| pulmonary |
283 |
| axial spondyloarthritis |
155 |
| musculoskeletal health questionnaire |
155 |
| reliability |
155 |
| validity |
155 |
| arthritis |
274, 264 |
| chondromatosis |
274 |
| hip |
274 |
| psoriatic |
274 |
| synovial |
274 |
| fever of unknown origin |
278 |
| infliximab |
278 |
| mycophenolate mofetil |
278 |
| pre-pulseless |
278 |
| takayasu arteritis |
278, 287 |
| clinical trial |
170 |
| disease-modifying anti-rheumatic drugs |
170 |
| opinercept |
170 |
| rheumatoid arthritis |
170, 163, 220, 247 |
| systemic lupus erythematosus |
239 |
| inflammatory back pain |
254, 189 |
| lupus |
254, 205 |
| sacroiliitis |
254 |
| autoimmune diseases |
259 |
| concomitant |
259 |
| sarcoidosis |
259, 226 |
| granulomatosis with polyangiitis |
292 |
| orbital inflammation |
292 |
| ocular prosthesis |
292 |
| orbital wall destruction |
292 |
| etanercept |
163 |
| predictive factors |
163 |
| treatment failure |
163 |
| lumbar disc herniation |
189 |
| spondyloarthritis |
189 |
| nephritis |
205 |
| productivity |
205 |
| work |
205 |
| interincisal distance |
196 |
| microstomia |
196 |
| mouth opening |
196 |
| systemic sclerosis |
196 |
| fear of movement |
214 |
| fibromyalgia |
214 |
| kinesiophobia |
214 |
| vitamin d |
214 |
| glomerulonephritis |
287 |
| neurologic manifestations |
287 |
| proteinuria |
287 |
| stroke |
287 |
| abatacept |
220 |
| fertility |
220 |
| safety |
220 |
| testicle |
220 |
| arab |
226 |
| jordan |
226 |
| world association of sarcoidosis and other granulomatous disorders |
226 |
| albumin |
247 |
| c-reactive protein |
247 |
| quality of life |
247 |
| elasticity |
264 |
| shear wave elastography |
264 |
| superb microvascular imaging |
264 |
| vascularity |
264 |
